NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-GM-19-001 from the NIH Guide for Grants and Contracts. Human induced pluripotent stem cells (iPSCs) have been used with great success to mimic the differentiation of a variety of tissues, understand early development and study human diseases. Despite approaches that have made the derivation, growth and differentiation of iPSCs more efficient, there remains significant variability in reprogramming efficacy, genomic integrity and developmental potential of iPSCs derived from a single fibroblast or tissue sample. Thus, iPSCs derived from the same sample may differ in their in vitro growth characteristics and their ability to re-differentiate into the desired tissue type. A variety of issues may affect derivation of the iPSCs and their growth, stability and differentiation, including the specific characteristics of the starting cell or tissue sample (e.g., age of donor, tissue type and anatomical location, physiological and disease state), the methods and protocols used to induce pluripotency (e.g., transcription factors, small molecules, cell fusion), the choice of growth factors and other culture conditions, method of storage of cell lines, etc. Further challenges include growing and maintaining sufficient quantities of iPSC lines in culture without changes in their properties, as well as the ability of multiple investigators to identify and authenticate iPSC lines as part of their research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.
Notice NOT-OD-19-108 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-TR-19-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.
Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, developmental biology, genetics, immunology, neuroscience, pharmacology, physiology, and technology development. In addition to the laboratory experience, the PRAT program provides a structured training environment with extensive career and professional development, mentoring, and networking opportunities planned and supported by the program.
Notice NOT-DA-19-046 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that propose to establish Offices of Sponsored Programs (OSPs) or enhance the services of existing OSPs or similar entities at domestic institutions of higher learning. Program priorities include funding primarily undergraduate institutions with emerging biomedical research and/or undergraduate research training programs.
Notice NOT-OD-19-110 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-059 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-20-013 from the NIH Guide for Grants and Contracts. NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.
Notice NOT-GM-19-041 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-20-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs
Funding Opportunity RFA-DA-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs
Funding Opportunity PAR-19-281 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).
Funding Opportunity PAR-19-282 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)
Notice NOT-MH-19-029 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-011 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-036 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-060 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-024 from the NIH Guide for Grants and Contracts